SFM
CMPX icon

Sphera Funds Management’s Compass Therapeutics CMPX Stock Holding History

Sphera Funds Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-700,000
Closed -$2.22M – 78
2021
Q4 		$2.22M Buy
+700,000
New +$2.32M 0.24% 72

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sphera Funds Management's CMPX Position: Q1 2022 in Review

Sphera Funds Management sold out of Compass Therapeutics (CMPX) in Q1 2022, closing a stake of 700,000 shares — an estimated $2.22M sold.

Sphera Funds Management first reported a position in CMPX in Q4 2021 and held it in 1 quarter. The position peaked at $2.22M in Q4 2021. 34 funds tracked by Wall St. Rank hold CMPX as of Q1 2022.

  • Sphera Funds Management reported no remaining Compass Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Sphera Funds Management sold 700,000 Compass Therapeutics shares in Q1 2022, an estimated $2.22M.
  • Sphera Funds Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 1 quarter.
  • Sphera Funds Management's Compass Therapeutics position peaked at $2.22M in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2022.

Based on Sphera Funds Management's 13F filing for Q1 2022, filed 16 May 2022.